Critical outcomes: All-cause mortality Health-related quality of life Unplanned hospitalisation Important outcomes: Other adverse events (stroke, bradycardia, hypotension) Improvement of NYHA class 6 Intervention What is the clinical and cost effectiveness of mineralocorticoid receptor antagonists in people with heart failure with preserved ejection fraction? Critical outcomes: All-cause mortality Quality of life Unplanned hospitalisation Important outcomes: Improvement of NYHA class Adverse events - Renal function Adverse events Gynaecomastia Adverse events Hypotension Adverse events - Hyperkalaemia 6 Intervention What is the clinical and cost effectiveness of adding a mineralocorticoid receptor antagonist to existing standard first line treatment in people with heart failure with reduced ejection fraction? Critical outcomes: All-cause mortality Quality of life Unplanned hospitalisation Important outcomes: Improvement of NYHA class Adverse events - Renal function Adverse events Gynaecomastia Adverse events Hypotension Adverse events - Hyperkalaemia 6 Intervention What is the clinical and cost effectiveness of iron supplementation in people with chronic heart failure and iron deficiency? Critical outcomes: Mortality Quality of life Unplanned hospitalisation Important outcomes: Improvement in exercise Chronic Heart Failure Methods NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Chapter Type of review Review questions Outcomes tolerance Change in haemoglobin in anaemic patients Withdrawal due to adverse events/tolerability Adverse events (hypertension, anaphylaxis/hypersensitivity, stroke, gastrointestinal) 6 Intervention What is the clinical and cost effectiveness of pharmacological interventions for heart failure in people with heart failure who also have chronic kidney disease? 